# Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

> **NCT04905407** · PHASE2 · TERMINATED · sponsor: **Syros Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Tamibarotene
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04905407
- **Lead sponsor:** Syros Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-26
- **Primary completion:** 2024-08-12
- **Final completion:** 2024-08-12
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** As per sponsor decision, the study was terminated.
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04905407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04905407, "Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04905407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*